The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels

R. Testa, S. M. Marcovina

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Lipoprotein(a) levels are largely genetically determined and are linked to increased risk of coronary artery disease. The hypothesis that elevated lipoprotein(a) levels lead to decreased fibrinolysis, due to the close structural homology with plasminogen, could in part explain the genesis of this risk, although contrasting results have been obtained in different studies. The aim of our study was to evaluate whether the rate of plasmin formation, enhanced in vitro by a fixed amount of human tissue plasminogen activator after clotting, was related to plasma lipoprotein(a) levels in 45 healthy subjects. Aliquots of human plasma were clotted with calcium chloride and thrombin followed by addition of tissue plasminogen activator. We then measured the time course of plasmin formation, determined as hydrolysis of H-D-valyl-L-leucylL-lysine-p-nitroanilide dihydrocortide (S-2251). The log of lipoprotein(a) level was negatively related to the rate of plasmin formation (r(s)=-0.46, P=0.002), and multiple regression analysis indicated that this relationship was not influenced by the amount of plasminogen, fibrinogen, plasminogen activator inhibitor-1, tissue plasminogen activator, or by the size of apo(a) isoforms. These data support the concept that lipoprotein(a) can inhibit plasminogen activation and plasmin formation and can thereby play an important role in the genesis of atherosclerosis as an antifibrinolytic agent.

Original languageEnglish
Pages (from-to)128-132
Number of pages5
JournalInternational Journal of Clinical & Laboratory Research
Volume29
Issue number3
DOIs
Publication statusPublished - Nov 1999

Fingerprint

Lipoprotein(a)
Fibrinolysin
Plasminogen
Plasmas
Tissue Plasminogen Activator
valyl-leucyl-lysine 4-nitroanilide
Plasma (human)
Calcium Chloride
Antifibrinolytic Agents
Plasminogen Activator Inhibitor 1
Fibrinolysis
Regression analysis
Thrombin
Fibrinogen
Lysine
Coronary Artery Disease
Hydrolysis
Atherosclerosis
Healthy Volunteers
Protein Isoforms

Keywords

  • Fibrinolysis
  • Lipoprotein(a)
  • Plasmin formation

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels. / Testa, R.; Marcovina, S. M.

In: International Journal of Clinical & Laboratory Research, Vol. 29, No. 3, 11.1999, p. 128-132.

Research output: Contribution to journalArticle

@article{f9d9684fb90a47fc8b05e42166c38ce3,
title = "The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels",
abstract = "Lipoprotein(a) levels are largely genetically determined and are linked to increased risk of coronary artery disease. The hypothesis that elevated lipoprotein(a) levels lead to decreased fibrinolysis, due to the close structural homology with plasminogen, could in part explain the genesis of this risk, although contrasting results have been obtained in different studies. The aim of our study was to evaluate whether the rate of plasmin formation, enhanced in vitro by a fixed amount of human tissue plasminogen activator after clotting, was related to plasma lipoprotein(a) levels in 45 healthy subjects. Aliquots of human plasma were clotted with calcium chloride and thrombin followed by addition of tissue plasminogen activator. We then measured the time course of plasmin formation, determined as hydrolysis of H-D-valyl-L-leucylL-lysine-p-nitroanilide dihydrocortide (S-2251). The log of lipoprotein(a) level was negatively related to the rate of plasmin formation (r(s)=-0.46, P=0.002), and multiple regression analysis indicated that this relationship was not influenced by the amount of plasminogen, fibrinogen, plasminogen activator inhibitor-1, tissue plasminogen activator, or by the size of apo(a) isoforms. These data support the concept that lipoprotein(a) can inhibit plasminogen activation and plasmin formation and can thereby play an important role in the genesis of atherosclerosis as an antifibrinolytic agent.",
keywords = "Fibrinolysis, Lipoprotein(a), Plasmin formation",
author = "R. Testa and Marcovina, {S. M.}",
year = "1999",
month = "11",
doi = "10.1007/s005990050077",
language = "English",
volume = "29",
pages = "128--132",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels

AU - Testa, R.

AU - Marcovina, S. M.

PY - 1999/11

Y1 - 1999/11

N2 - Lipoprotein(a) levels are largely genetically determined and are linked to increased risk of coronary artery disease. The hypothesis that elevated lipoprotein(a) levels lead to decreased fibrinolysis, due to the close structural homology with plasminogen, could in part explain the genesis of this risk, although contrasting results have been obtained in different studies. The aim of our study was to evaluate whether the rate of plasmin formation, enhanced in vitro by a fixed amount of human tissue plasminogen activator after clotting, was related to plasma lipoprotein(a) levels in 45 healthy subjects. Aliquots of human plasma were clotted with calcium chloride and thrombin followed by addition of tissue plasminogen activator. We then measured the time course of plasmin formation, determined as hydrolysis of H-D-valyl-L-leucylL-lysine-p-nitroanilide dihydrocortide (S-2251). The log of lipoprotein(a) level was negatively related to the rate of plasmin formation (r(s)=-0.46, P=0.002), and multiple regression analysis indicated that this relationship was not influenced by the amount of plasminogen, fibrinogen, plasminogen activator inhibitor-1, tissue plasminogen activator, or by the size of apo(a) isoforms. These data support the concept that lipoprotein(a) can inhibit plasminogen activation and plasmin formation and can thereby play an important role in the genesis of atherosclerosis as an antifibrinolytic agent.

AB - Lipoprotein(a) levels are largely genetically determined and are linked to increased risk of coronary artery disease. The hypothesis that elevated lipoprotein(a) levels lead to decreased fibrinolysis, due to the close structural homology with plasminogen, could in part explain the genesis of this risk, although contrasting results have been obtained in different studies. The aim of our study was to evaluate whether the rate of plasmin formation, enhanced in vitro by a fixed amount of human tissue plasminogen activator after clotting, was related to plasma lipoprotein(a) levels in 45 healthy subjects. Aliquots of human plasma were clotted with calcium chloride and thrombin followed by addition of tissue plasminogen activator. We then measured the time course of plasmin formation, determined as hydrolysis of H-D-valyl-L-leucylL-lysine-p-nitroanilide dihydrocortide (S-2251). The log of lipoprotein(a) level was negatively related to the rate of plasmin formation (r(s)=-0.46, P=0.002), and multiple regression analysis indicated that this relationship was not influenced by the amount of plasminogen, fibrinogen, plasminogen activator inhibitor-1, tissue plasminogen activator, or by the size of apo(a) isoforms. These data support the concept that lipoprotein(a) can inhibit plasminogen activation and plasmin formation and can thereby play an important role in the genesis of atherosclerosis as an antifibrinolytic agent.

KW - Fibrinolysis

KW - Lipoprotein(a)

KW - Plasmin formation

UR - http://www.scopus.com/inward/record.url?scp=0032787139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032787139&partnerID=8YFLogxK

U2 - 10.1007/s005990050077

DO - 10.1007/s005990050077

M3 - Article

VL - 29

SP - 128

EP - 132

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 3

ER -